Physician profile
Daniel Rohweder
NPI 1508958729
$20,890.96
in general payments reported to CMS, 2019-2025
79 companies · $568 in 2025
The $568 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,941 · 2020: $3,702 · 2021: $3,687 · 2022: $2,995 · 2023: $2,799 · 2024: $3,199 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,566.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,754.67 | 2019-2025 | Vraylar, Ubrelvy, Linzess |
| Allergan, INC. | $2,602.92 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $1,400.43 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $944.16 | 2019-2024 | Mounjaro, Emgality, Jardiance |
| Janssen Pharmaceuticals, INC | $908.46 | 2019-2024 | Xarelto, Spravato |
| Amgen INC. | $904.27 | 2019-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $805.73 | 2019-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $752.84 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $718.93 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $698.37 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $644.69 | 2019-2024 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $631.13 | 2019-2025 | Rexulti, Abilify Maintena |
| Supernus Pharmaceuticals, INC. | $524.93 | 2023-2024 | Qelbree, Qelbree |
| Gilead Sciences, INC. | $392.67 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $350.17 | 2019-2024 | Vaxneuvance, Gardasil 9, Gardasil |
Show all 79 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rohweder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.